Acute lymphoblastic leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 122
• CD22 33
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  TOWARDS THE ELIMINATION OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN THROUGH IDENTIFICATION OF THEIR ENVIRONMENTAL CAUSES (ELI-ALL)

  Centre International de Recherche Sur Le Cancer· Lyon 7eme, France· EU contribution €6,502,240· until Aug 2031· 12 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX (THANATOS)

  Commissariat A L Energie Atomique Et Aux Energies Alternatives· Paris, France· EU contribution €13,557,641· until Aug 2031· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of RAS mutant subclones in the development of High Hyperdiploid B-ALL (RasWayToALL)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €200,400· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Science, Innovation, Health, Earth, And Life Technologies for ALL (SCIENCE4ALL)

  Istinye University· Istanbul, Türkiye· EU contribution €350,000· until Jun 2028

5 of 13 running projects, newest first. Listed amounts together: €62.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics.

  Biomolecules, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.